NEWS
TransCode Therapeutics Completes Initial Dosing of First Cohort in Phase 1 Clinical Trial with TTX-MC138, a microRNA-Targeted Technology
TransCode Therapeutics (NASDAQ: RNAZ) has completed initial dosing of the first cohort in its Phase 1a dose-escalation clinical trial for TTX-MC138, an antisense oligonucleotide designed to inhibit microRNA-10b, a driver of metastasis in multiple cancers. Key points:
All patients in the cohort received their first dose and remain on study for continued treatment
No significant safety or dose limiting toxicities reported
TTX-MC138 uses TransCode's proprietary TTX delivery system
TransCode is the only company with an ongoing US clinical trial targeting microRNA in cancer
The trial's progress coincides with the 2024 Nobel Prize in Physiology and Medicine recognizing microRNA technology
The company views the rapid enrollment and absence of dose limiting toxicities as encouraging signs for the continued assessment of TTX-MC138's safety and tolerability.
TransCode Therapeutics (NASDAQ: RNAZ) has completed initial dosing of the first cohort in its Phase 1a dose-escalation clinical trial for TTX-MC138, an antisense oligonucleotide designed to inhibit microRNA-10b, a driver of metastasis in multiple cancers. Key points:
All patients in the cohort received their first dose and remain on study for continued treatment
No significant safety or dose limiting toxicities reported
TTX-MC138 uses TransCode's proprietary TTX delivery system
TransCode is the only company with an ongoing US clinical trial targeting microRNA in cancer
The trial's progress coincides with the 2024 Nobel Prize in Physiology and Medicine recognizing microRNA technology
The company views the rapid enrollment and absence of dose limiting toxicities as encouraging signs for the continued assessment of TTX-MC138's safety and tolerability.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
Spread kindness and love. Life is short. Don’t let greed eat you.
2592Followers
107Following
28KVisitors
Follow